


Medicare Coverage

This information is current as of June 2008. The information provided here is compiled from sources believed to be accurate but Merck makes no representation that it is accurate. As a provider, you are solely responsible for billing third-party payers correctly, and you should determine if any payer-specific guidelines or policies apply. It is the responsibility of each provider to ensure that the billing and coding for all services and products are appropriate and correct. Merck does not guarantee or assure the timeliness or appropriateness of this information for your particular use given the frequent changes in public and private payer billing.

When prescribing **EMEND® for Injection** (fosaprepitant dimeglumine) and the **Bifold Pack of EMEND®** (aprepitant)...

DAY
1




EMEND for Injection—Eligible for Medicare Part B coverage when:

- Considered to be of the type of injectable drug that is not usually self-administered, *and*
- Considered to be incident to a physician's services, *and*
- Reasonable and necessary for diagnosis or treatment of the illness or injury for which it is administered

Check with your local carrier or A/B MAC for applicable policies and procedures.

DAYS
2&3



When prescribing the Bifold Pack of EMEND following EMEND for Injection, you can use the prescription stamp (shown at right) or write on the prescription "EMEND for Injection administered prior to chemotherapy" to provide information that may be necessary to process the prescription under Medicare Part D.

Part D

The Bifold Pack of EMEND is eligible for Medicare Part D coverage when used after EMEND for Injection.^a

R_x
EMEND® (aprepitant): Bifold pack
Dispense: _____ Bifold pack(s)
Sig: One Bifold pack for each chemotherapy cycle as follows:
• One day after chemotherapy: one 80mg capsule qAM PO.
• Two days after chemotherapy: one 80mg capsule qAM PO.
Refills: _____ Bifold pack(s)
Note to pharmacist: This Bifold pack prescription is a continuation of the following therapy which was administered prior to chemotherapy (check one):
<input checked="" type="checkbox"/> EMEND for Injection® (fosaprepitant dimeglumine) 115mg I.V.
<input type="checkbox"/> EMEND® (aprepitant) 125mg capsule PO.

EMEND, in combination with other antiemetic agents, is indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin; and for prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

Selected Important Risk Information

EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozone, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.

EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT₃ receptor antagonist. The recommended dosage includes EMEND (125 mg) on Day 1 followed by EMEND (80 mg) once daily on Days 2 and 3. **EMEND for Injection (115 mg) may be substituted for EMEND 30 minutes before chemotherapy, on Day 1 only, as an infusion administered over 15 minutes.**


EMEND®
(aprepitant)

EMEND®
(fosaprepitant dimeglumine)
for Injection

Vial, packs, and capsule not shown at actual size.

When prescribing the **Trifold Pack of EMEND®** (aprepitant) or an **oral regimen of EMEND...**

**DAYS
1-3**



Part B

The Bifold Pack of EMEND is covered under Medicare Part B when used after EMEND 125 mg and when criteria of the National Coverage Determination for Aprepitant are met.

R_x

EMEND® (aprepitant): Bifold pack

Dispense: _____ Bifold pack(s)

Sig: One Bifold pack for each chemotherapy cycle as follows:

- One day after chemotherapy: one 80mg capsule qAM P.O.
- Two days after chemotherapy: one 80mg capsule qAM P.O.

Refill(s): _____ Bifold pack(s)

Note to pharmacist: This Bifold pack prescription is a continuation of the following therapy which was administered prior to chemotherapy (check one):

EMEND for Injection* (fosaprepitant dimeglumine) 115mg I.V.

EMEND® (aprepitant) 125mg capsule P.O.

To facilitate Medicare claims processing when using 3 days of oral EMEND, you can use the prescription stamp (shown above) and the sticker (shown below) to provide relevant information when prescribing the Bifold Pack of oral EMEND. This may assist your Medicare patients at the pharmacy.

Criteria of the Medicare Part B National Coverage Determination for Aprepitant _____

If an all-oral regimen (3 days) of EMEND does not meet the criteria of the Medicare Part B National Coverage Determination for Aprepitant, coverage may be available under Medicare Part D^a _____

Medicare Part B

Aprepitant was prescribed

- In combination with an oral 5-HT₃ receptor antagonist and oral dexamethasone

AND

- For a patient receiving 1 or more of the following anticancer chemotherapeutic agents: carmustine, cisplatin, cyclophosphamide, dacarbazine, mechlorethamine, streptozocin, doxorubicin, epirubicin, or lomustine.

OR

Medicare Part D

Aprepitant was prescribed for a medically accepted indication that is not in accordance with the Medicare Part B coverage guidelines found in the National Coverage Decision for Aprepitant.

^aUnder Medicare Part D, the availability and amount of reimbursement for individual patients will vary based, for example, on the patient's benefit design, including the application of any deductible, copay, or coverage limit. You or the patient should contact the Part D plan for the most up-to-date patient-specific coverage and reimbursement information.

Selected Important Risk Information

EMEND should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4. Inhibition of CYP3A4 by EMEND could result in elevated plasma concentrations of these concomitant medications. Conversely, when EMEND is used concomitantly with another CYP3A4 inhibitor, aprepitant plasma concentrations could be elevated.

Because a small number of patients in clinical studies received the CYP3A4 substrates vinblastine, vincristine, or ifosfamide, particular caution and careful monitoring are advised in patients receiving these agents or other chemotherapy agents metabolized primarily by CYP3A4 that were not studied.

Before prescribing EMEND or EMEND for Injection, please read the accompanying Prescribing Information. For additional copies of the Prescribing Information, call 800-672-6372, visit emend.com or emendforinjection.com, or contact your Merck representative.

EMEND is a registered trademark of Merck & Co., Inc.



Copyright © 2008 Merck & Co., Inc. All rights reserved. 20805747(1)-07/08-EME
Printed in USA Minimum 10% Recycled Paper

emend.com emendforinjection.com

EMEND®
(aprepitant)

EMEND®
(fosaprepitant dimeglumine)
for Injection